NeoCart: Phase II data

An open-label, U.S. Phase II trial in 30 patients showed that NeoCart met the primary endpoint of significantly improving

Read the full 197 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE